NVCR vs BEAM Stock Comparison: AI Score, Valuation, Performance and Upside
NVCR is a commercial-stage medical device company generating revenue from its TTFields cancer therapy platform while pursuing clinical expansion into larger cancer markets, while BEAM is a preclinical/early-clinical gene editing biotech with no approved products but a promising precision editing technology. These represent different stages of biomedical innovation investment.
NVCR vs BEAM contrasts a commercial medical device company expanding its cancer therapy into new indications against a precision gene editing biotech pursuing curative therapies for genetic diseases, both representing frontier biomedical technologies.
BEAM holds the edge across 3 of 5 key metrics in this comparison. BEAM leads on both 1-year return (+22.21%) and forward P/E quality (-5.06x vs -21.84x for NVCR), a relatively favorable combination of momentum and valuation. NVCR leads on both revenue growth (15.60%) and operating margin (-5.75%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BEAM (+117.40%) than for NVCR (+52.23%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want commercial biomedical innovation exposure with existing revenue from approved GBM and mesothelioma indications
- See the EF-32 lung cancer trial as a high-value clinical binary catalyst that could dramatically expand the addressable market
- Value TTFields' additive mechanism as combining with existing cancer therapies rather than replacing them, reducing adoption hurdles
- Want early-stage exposure to base editing gene therapy technology with potential for curative treatments in genetic diseases
- Value Beam's proprietary base editing chemistry as a differentiated precision approach versus traditional CRISPR cutting
- Are comfortable with clinical-stage biotechnology risk and long development timelines in exchange for potentially transformative disease-modifying therapy potential
| Metric | NVCR | BEAM |
|---|---|---|
| AI scorei | 35.6 | 31.5 |
| AI ranki | #1682 | #2220 |
| Latest closei | $14.61 | $27.79 |
| 1M returni | -3.88% | +8.26% |
| 3M returni | -8.97% | +2.66% |
| 6M returni | -11.43% | -14.07% |
| 1Y returni | +21.75% | +22.21% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVCR | BEAM |
|---|---|---|
| 1Y ago | $12.18K (+21.7%) started 2025-11-04 | $12.22K (+22.2%) started 2025-11-04 |
| 5Y ago | $1.37K (-86.3%) started 2021-11-05 | $3.1K (-69.0%) started 2021-11-05 |
| 10Y ago | $20.15K (+101.5%) started 2016-11-07 | $14.82K (+48.2%) started 2020-02-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | NVCR | BEAM |
|---|---|---|
| Market capi | $2.08B | $2.48B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -21.84 | -5.06 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 2.60 | 9.56 |
| Analyst targeti | $27.14 | $52.15 |
| Target upsidei | +52.23% | +117.40% |
| Metric | NVCR | BEAM |
|---|---|---|
| Revenue growthi | 15.60% | -94.20% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +3.26% | -154.99% |
| Operating margini | -5.75% | -25827.14% |
| Profit margini | -21.25% | -55.45% |
| ROIC proxyi | -43.22% | -8.18% |
| Return on equityi | -43.22% | -8.18% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.98 | 2.23 |
| Debt/equityi | 69.04 | 23.17 |
| Current ratioi | 2.89 | 14.57 |
| Quick ratioi | 2.66 | 14.25 |
Over the past year, NVCR and BEAM have moved weakly in the same direction (correlation of 0.23), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | NVCR | BEAM |
|---|---|---|---|
| 1Y | Growthi | +21.75% | +22.21% |
| CAGRi | +21.77% | +22.22% | |
| Volatilityi | 80.51% | 71.56% | |
| Sharpe ratioi | 0.57 | 0.57 | |
| Sortino ratioi | 0.98 | 0.92 | |
| Max drawdowni | 34.42% | 39.08% | |
| Current drawdowni | 26.91% | 26.71% | |
| Avg drawdowni | 13.90% | 19.14% | |
| Ulcer Indexi | 16.80% | 22.39% | |
| Max daily dropi | 20.00% | 10.48% | |
| Max wkly dropi | 23.81% | 20.74% | |
| 5Y | Growthi | -86.27% | -68.96% |
| CAGRi | -32.79% | -20.87% | |
| Volatilityi | 81.56% | 75.32% | |
| Sharpe ratioi | -0.15 | -0.00 | |
| Sortino ratioi | -0.23 | -0.00 | |
| Max drawdowni | 91.56% | 85.32% | |
| Current drawdowni | 87.70% | 71.95% | |
| Avg drawdowni | 68.72% | 66.02% | |
| Ulcer Indexi | 73.16% | 67.78% | |
| Max daily dropi | 43.04% | 19.32% | |
| Max wkly dropi | 46.39% | 31.25% | |
| 10Y | Growthi | +101.52% | +48.21% |
| CAGRi | +7.27% | +6.01% | |
| Volatilityi | 71.90% | 79.53% | |
| Sharpe ratioi | 0.38 | 0.41 | |
| Sortino ratioi | 0.61 | 0.63 | |
| Max drawdowni | 95.55% | 89.12% | |
| Current drawdowni | 93.52% | 79.20% | |
| Avg drawdowni | 49.30% | 60.99% | |
| Ulcer Indexi | 61.58% | 66.38% | |
| Max daily dropi | 43.04% | 23.42% | |
| Max wkly dropi | 46.39% | 41.11% |
| Category | NVCR | BEAM |
|---|---|---|
| Company | NovoCure Limited | Beam Therapeutics Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
| Core business | NovoCure's Tumor Treating Fields (TTFields) technology delivers alternating electric fields to tumors using wearable devices, disrupting cancer cell division. It's commercially approved for glioblastoma (GBM) and mesothelioma, with clinical trials in lung cancer, pancreatic cancer, and other solid tumors. | Beam Therapeutics is developing base editing medicines — a next-generation gene editing approach that makes precise single-letter changes to DNA rather than causing double-strand cuts — for genetic blood diseases (sickle cell, beta-thalassemia) and liver diseases. |
| Investor focus | Investors track NovoCure's active patient count growth, net revenue per patient, payer coverage expansion (particularly commercial insurance in the U.S. and country approvals internationally), and the EF-32 lung cancer trial result as the most important pipeline catalyst. | Investors track Beam's clinical trial progress in hematological diseases (BEAM-101, BEAM-102), base editing safety and efficacy data, manufacturing platform development, and the company's cash position relative to its development timeline. |
- Commercial revenue from two approved indications (GBM and MPM) provides a foundation while pipeline trials proceed in larger cancer indications
- Lung cancer (EF-32 trial) represents a massive expansion opportunity — lung cancer is among the most common cancers globally with limited breakthrough therapies
- TTFields mechanism is additive to chemotherapy, immunotherapy, and radiation — potential combinations multiply indication opportunities
- Base editing technology makes more precise DNA edits than traditional CRISPR — changing individual DNA letters rather than cutting and rejoining, potentially reducing off-target editing risks
- Sickle cell disease and beta-thalassemia are large, well-validated genetic disease targets where gene editing has shown dramatic clinical benefit
- Proprietary base editing chemistry provides intellectual property foundation and potential for multiple disease applications
- GBM is a rare cancer — the approved market size limits total addressable revenue without successful expansion into larger cancer indications
- EF-32 lung cancer trial failure would be a major setback to the investment thesis centered on market expansion
- Payer reimbursement challenges for TTFields outside the U.S. and Medicare GBM coverage slow international revenue growth
- Base editing and CRISPR are pre-revenue biotechnology technologies — Beam has no approved products and uncertain commercialization timelines
- Clinical trial safety data are critical — gene editing therapies must demonstrate no significant off-target editing effects
- Competition from Vertex/CRISPR Therapeutics (Casgevy) and Bluebird Bio (Lyfgenia) which already have approved sickle cell therapies
Compare more than two at a time
This page is a fixed writeup on NVCR and BEAM. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside NVCR and BEAM, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.